Theratechnologies Inc. (THTX), a biopharmaceutical company, Tuesday announced the resubmission of its supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration or FDA for the F8 formulation of tesamorelin.
Tesamorelin is approved in the U.S. for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy.
The F8 Formulation is bioequivalent to the original formulation of tesamorelin, or F1 Formulation, sold as EGRIFTA.
Theratechnologies expects a decision from the FDA by the end of March 2025.
In January this year, the FDA had issued a Complete Response Letter (CRL) to the initial F8 formulation sBLA filing. The regulator had requested clarifications mainly related to chemistry, manufacturing and controls (CMC), as well as further information on immunogenicity risk.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.